Introduction {#Sec1}
============

Traditional approaches for the risk and safety assessment of compounds rely heavily on toxicity data derived from laboratory animals, which are gradually being recognized as inappropriate models for the prediction of human health effects due to toxicodynamic and toxicokinetic differences between animals and human (Ewart et al. [@CR38]; Pang et al. [@CR85]). This consideration as well as the fact that animal-based testing strategies are cost and labor intensive, while also increasingly considered unethical, has stimulated the development of novel testing strategies, leading to a paradigm shift in toxicity testing (Judson et al. [@CR52]). Novel testing strategies generally apply in vitro assays and take into account insight in the modes of action underlying the toxicity (Bernauer et al. [@CR17]). However, in vitro assays provide hazard information and concentration--response curves that require translation to corresponding human dose--response curves, taking into account human toxicokinetics, to enable their use in human risk and safety assessment of compounds (Bell et al. [@CR15]; Blaauboer [@CR18]).

Over the last decade, several proof-of-principle studies indicated that combining in vitro toxicity assays with physiologically based kinetic (PBK) modeling, which describes the absorption, distribution, metabolism and excretion (ADME) of a compound in a defined species, can adequately predict in vivo dose--response curves (Louisse et al. [@CR70]; Rietjens et al. [@CR90]). For example, quantitative in vitro to in vivo extrapolation (QIVIVE) using PBK modeling-based reverse dosimetry was shown to adequately predict the in vivo toxicity for different endpoints, including developmental toxicity (Li et al. [@CR68]; Louisse et al. [@CR69]; Strikwold et al. [@CR96], [@CR97]), liver toxicity (Ning et al. [@CR82]), nephrotoxicity (Abdullah et al. [@CR1]) and neurotoxicity (Zhao et al. [@CR117]). To further explore the potential applicability of this in vitro--in silico approach, the aim of the present study was to investigate whether the PBK modeling-based reverse dosimetry can be extended to predict in vivo cardiotoxicity in human, thereby providing a novel testing strategy for cardiac safety testing.

Cardiotoxicity is an important endpoint in pharmaceutical safety testing and has been a leading cause of drug attrition in preclinical drug development (Pang et al. [@CR85]; Stevens and Baker [@CR95]). In addition, cardiotoxicity is also a relevant endpoint in food safety, given that many food-borne alkaloids from botanicals and botanical preparations, including, for example, synephrine from bitter orange (*Citrus aurantium*) and nuciferine from lotus (*Nelumbo nucifera*), raise a concern with respect to potential cardiotoxicity (Kratz et al. [@CR63]). Potential cardiotoxicity includes functional and structural disruption of the cardiovascular system by interfering with ion channels, intracellular organelles and cellular signaling pathways (Clements et al. [@CR27]; Pang et al. [@CR85]). Particularly, cardiac electrophysiological alterations such as delayed ventricular repolarization are endpoints of interest for cardiac safety assessment. Delayed ventricular repolarization can result in a prolonged QTc interval (time from ventricular depolarization and repolarization corrected for heart rate) in the electrocardiogram (ECG) which is associated with increased risk of arrhythmia including polymorphic ventricular tachyarrhythmia (torsade de pointes, Tdp) (Ewart et al. [@CR37]; Harris et al. [@CR48]; Kannankeril et al. [@CR54]; Redfern et al. [@CR88]; Wakefield et al. [@CR109]). Current regulatory guidelines to evaluate in vitro electrophysiological cardiotoxicity are based on ion channel inhibition assays using cell lines transfected with specific ion channels, including especially human ether-à-go-go-related gene (hERG) channels which play a critical role in cardiac repolarization (ICH [@CR101]; Martin et al. [@CR75]; Zwartsen et al. [@CR118]). However, such an approach focussing on a single type of ion channel fails to address effects induced on other channels (Mirams et al. [@CR76]; Rehnelt et al. [@CR89]). Recently, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) have been reported to provide a physiological relevant in vitro model for human cardiotoxicity testing. These hiPSC-CM express major cardiac ion channels and show typical electrophysiological responses upon the exposure to compounds (Garg et al. [@CR45]; Ma et al. [@CR72]). In the present study, hiPSC-CM were applied in combination with the multi electrode array (MEA) technique measuring the extracellular field potential of electrically active cardiomyocytes, which is considered a promising tool to assess electrophysiological alteration and arrhythmias (Ando et al. [@CR7]; Harris et al. [@CR48]; Kitaguchi et al. [@CR60]; Li et al. [@CR67]). The parameters obtained from extracellular field potential waveforms are considered to resemble the parameters observed in the human ECG (Zwartsen et al. [@CR118]), which allows use of the hiPSC-CM MEA assay as an adequate in vitro model for QIVIVE.

The model compound selected for the present study was methadone (Fig. [1](#Fig1){ref-type="fig"}). Methadone is a synthetic drug for the treatment of opioid dependence and chronic pain. Methadone is metabolized by cytochromes P450 (CYP) mainly in the liver (Eap et al. [@CR33]; Nilsson et al. [@CR81]). The primary metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), is formed via *N*-demethylation and cyclisation, and a subsequent *N*-demethylation leads to the secondary metabolite, 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) (Fig. [1](#Fig1){ref-type="fig"}). Methadone has been reported to cause cardiotoxic side effects in human clinical studies in which prolonged QTc interval and TdP have been observed in subjects receiving methadone maintenance treatment (Alinejad et al. [@CR5]; Eap et al. [@CR33]; Justo et al. [@CR53]). Several in vitro studies using electrophysiological-based patch clamp demonstrated an association between the cardiotoxicity of methadone and the inhibition of hERG channels (Eap et al. [@CR31]; Kuryshev et al. [@CR64]).Fig. 1Metabolic conversion of methadone to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) by cytochrome P450 (CYP450)

In the present study, the in vitro concentration-dependent cardiotoxicity of methadone and its metabolites EDDP and EMDP was quantified in hiPSC-CM using the MEA technique. Additionally, a PBK model for methadone kinetics in human was developed by integrating data from literature as well as experimentally obtained metabolic parameters. This PBK model was subsequently used to translate the in vitro toxicity data to predict in vivo cardiotoxicity in human. The data thus obtained were compared to available data on the effect of methadone on cardiac parameters in subjects that received methadone maintenance treatment.

Materials and methods {#Sec2}
=====================

Chemical and biological materials {#Sec3}
---------------------------------

Methadone hydrochloride (≥ 98%), EDDP perchlorate (≥ 98%), EMDP hydrochloride solution (1.0 mg/ml), Tris (hydroxymethyl) aminomethane (Trizma^®^ base), ammonium formate and fibronectin were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Methadone and metabolites were ordered under the opium exemption license number 104783 03 WCO, which is registered at Farmatec (executive organization of the Ministry of Health, Welfare and Sport, The Hague, The Netherlands). Dimethyl sulfoxide (DMSO, 99.7%) was obtained from Merck (Schiphol-Rijk, The Netherlands). Phosphate-buffered saline (PBS) was purchased from Gibco (Paisley, Scotland, UK). Acetonitrile (UPLC/MS grade) was obtained from Biosolve BV (Valkenswaard, The Netherlands). hiPSC-CM (Pluricyte^®^ Cardiomyocytes, cat\# PCMI-1031-1, lot\# 60151) and Pluricyte^®^ Cardiomyocyte medium were obtained from Ncardia (Leiden, The Netherlands). Pooled human liver microsomes (from 150 donors), pooled human intestinal microsomes (from 7 donors) and reduced nicotinamide adenine dinucleotide phosphate (NADPH) regenerating system solution A and solution B were purchased from Corning (Woburn, MA, USA). Pooled human plasma and rapid equilibrium dialysis (RED) materials, including RED inserts, RED base plates and sealing tape were obtained from Thermo Fisher Scientific (Bleiswijk, The Netherlands).

General outline of the PBK modeling‑based reverse dosimetry approach {#Sec4}
--------------------------------------------------------------------

The PBK modeling-based reverse dosimetry approach to predict the in vivo dose--response curves from in vitro cardiotoxicity concentration--response data included the following steps: (1) establishment of the in vitro concentration--response curves for methadone and its metabolites EDDP and EMDP in hiPSC-CM using the MEA, (2) development of a PBK model for methadone and its metabolites in human using metabolic parameters obtained from in vitro incubations with pooled human liver microsomes, and parameters derived from in silico simulations and the literature, (3) evaluation of the PBK model, (4) translation of in vitro concentration--response curves to in vivo dose--response curves using the PBK model, and (5) evaluation of the PBK modeling-based reverse dosimetry approach by comparing predicted dose--response data to data obtained from literature on the effect of methadone on cardiac parameters in subjects receiving methadone maintenance treatment.

In vitro cardiotoxicity of methadone and metabolites in hiPSC-CM using the MEA {#Sec5}
------------------------------------------------------------------------------

The MEA system of Multi Channel System (MCS GmbH, Ruetlingen, Germany) combined with Pluricyte^®^ Cardiomyocytes was used to detect the cardiotoxicity of methadone, and the metabolites EDDP and EMDP. The Pluricyte^®^ Cardiomyocytes were thawed and seeded on the six-well MEA chips (60-6well MEA200/30iR-Ti-tcr, MCS GmbH) according to the manufacturer's protocol. Briefly, each well of the MEA chips was precoated with 50 μg/ml fibronectin for 3 h in the incubator at 37 °C with 5% CO~2~. The fibronectin coating solution was aspirated before seeding. Cells were thawed in the incubator at 37 °C for exactly 4 min and carefully transferred to a 50-ml tube. The original vial was rinsed with serum free Pluricyte^®^ Cardiomyocyte Medium and added drop-wise to the tube containing the cardiomyocytes. Subsequently, cell counting was manually performed, using 20 μl of obtained homogenous cell suspension in a Buerker-Tuerk Counting Chamber (Marienfeld Superior GmbH & Co. KG, Lauda-Königshofen, Germany) and at the same time the remaining cells were centrifuged at 300*g* for 3 min. Then, the supernatant was removed and medium was drop-wisely added to reach the aimed concentration of cells in the suspension (10^4^ cells/μl). 2-μl cell suspension per well was placed on the six-well MEA chips in a density of 10^4^ cells/μl. After 3-h incubation (37 °C, 5% CO~2~), 200 μl of medium was filled into each well of the MEA chips which were subsequently incubated at 37 °C with 5% CO~2~ and refreshed with medium every 2 days.

At 7--8 days after seeding, MEA chips were placed on the headstage of a MEA2100-system (MCS GmbH) integrated with the chamber providing a stable atmosphere (37 °C, 5% CO~2~) to record the extracellular field potential (Fig. [2](#Fig2){ref-type="fig"}) of spontaneous beating hiPSC-CM. After an equilibration time of 20 min, half of the medium (100 μl) in each well was replaced by culture medium containing 0.2% (v/v) DMSO to reach a final concentration of 0.1% (v/v) DMSO, which was used as baseline condition. Subsequently, the model compounds were tested in separate wells, and each test compound was cumulatively added to the well with increasing concentrations in the same way (Harris et al. [@CR48]; Nozaki et al. [@CR119]; Ando et al. [@CR7]). At each concentration, the extracellular field potential was recorded for 1 min after 10-min exposure. Stock solutions of model compounds were prepared in DMSO and further diluted in Pluricyte^®^ Cardiomyocyte medium to make exposure medium with the final concentration of 0.1% (v/v) DMSO. The following concentrations were tested, 0.01, 0.03, 0.1, 0.2, 0.3, 0.4, 1, 3, 10, 30 µM (methadone), 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 µM (EDDP) and 0.1, 0.3, 1, 3, 10, 30 µM (EMDP), at which no cytotoxicity was observed (data not shown). The test concentrations of methadone were based on reported human methadone plasma concentrations that were observed after oral methadone treatment. Same test concentrations were chosen for EDDP and EMDP, which enables definition of concentration-dependent curves for EDDP and EMDP that allow potency comparison.Fig. 2Typical extracellular field potential waveform consisting of a rapid upstroke corresponding to depolarization, a slow wave/plateau and a repolarization peak. Signals were generated under the baseline condition (0.1% (v/v) DMSO) in Pluricyte cardiomyocytes cultured in six-well MEA-chips measured by the MEA2100-System platform of MCS

One well of 0.1% (v/v) DMSO on each MEA chip was used as the vehicle control well and run at the same time as the compound exposure wells to correct for time- and DMSO-dependent effects on the field potential. A detailed exposure scheme can be found in Fig. S1. Data were collected using Cardio 2D software (MCS GmbH) with a sample frequency of 10 kHz and a 0.1--3.5-kHz band-pass filter.

After exposure, MEA data generated from the electrodes showing stable baseline field potential with clearly visible depolarization (peak amplitude ≥ 200 μV) and repolarization peaks (peak amplitude ≥ 20 μV) (Ando et al. [@CR7]; Sala et al. [@CR93]) were selected for further analysis using Multiwell-Analyzer software Version 1.5.1.0 (MCS GmbH). Field potential duration (FPD) was defined as duration between the beginning of the sodium spike and the repolarizing peak (Fig. [2](#Fig2){ref-type="fig"}). RR-intervals were defined as the duration between two depolarization peaks (Fig. [2](#Fig2){ref-type="fig"}). The FPD and RR-interval were measured as the average of at least 30 beats from 1-min recording at each concentration of the test compound. In addition, the Fridericia formula (Eq. [1](#Equ1){ref-type=""}) was applied to correct for the effect of beat rate on FPD (Vandenberk et al. [@CR106]) as widely used in other MEA studies (Ando et al. [@CR7]; Kitaguchi et al. [@CR60]):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{FPDc}} = \frac{{{\text{FPD}}}}{{\sqrt[3]{{{\text{RR}}\;{\text{interval}}}}}}.$$\end{document}$$

In this formula, the FPD and RR-interval are expressed in seconds. Data were collected from at least three independent experiments (4--8 wells, 26--38 electrodes), using a new vial of cells (all from the same batch) at each independent experiment. In vitro cardiotoxic effects are expressed as relative percentage of FPDc compared to the FPDc results obtained for the baseline condition \[0.1% (v/v) DMSO\] and further corrected for the time- and DMSO-dependent effects by subtracting the response of 0.1% (v/v) DMSO obtained from the corresponding time-matched vehicle control well. The concentrations inducing irregularities in the field potential trace (Fig. S2) were also noted. Such irregularities included arrhythmia-type changes in the waveform, a flattened unclear second peak and/or beating arrest (Asakura et al. [@CR10]; Kitaguchi et al. [@CR60]; Nakamura et al. [@CR80]; Zwartsen et al. [@CR118]). Concentrations inducing these irregularities were excluded from the FPD analysis since the FPD and RR-interval could not be determined.

Effective concentrations expressed as the FPDc (% to the baseline control) were determined using the benchmark dose (BMD) approach which was performed as described in the "[Evaluation of the PBK modeling-based reverse dosimetry approach](#Sec13){ref-type="sec"}". The concentration--response curves were plotted with GraphPad Prism 5.0 using the four-parameters logistic fit (GraphPad Software Inc., San Diego, USA). Each data point is presented as the mean value of at least three independent experiments ± standard deviation (SD). Statistical significance of the changes in response of cells exposed to the compound compared to the solvent control was analyzed by one-way ANOVA followed by post Dunnett test. Values of *p* \< 0.05 were regarded as statistically significant (*p* \< 0.05: \*, *p* \< 0.01: \*\* and *p* \< 0.001: \*\*\*). Statistical analysis was performed by GraphPad Prism 5.0 (GraphPad Software Inc.).

In vitro microsomal incubations {#Sec6}
-------------------------------

In vitro incubations were performed to obtain the kinetic parameters for the conversion of methadone by human liver microsomes. To this end, incubation conditions were optimized to obtain linear reaction rates with respect to microsomal protein levels (0.1--2 mg/ml protein) and incubation time (1--120 min) at 50-µM methadone. The final incubation mixtures (final volume of 160 µl) consisted of 0.1-M Tris--HCl (pH 7.4--7.5), NADPH regeneration system (final concentrations 1.3-mM NADP^+^, 3.3-mM glucose-6-phosphate, 0.4-U/ml glucose-6-phosphate dehydrogenase and 3.3-mM magnesium chloride) and methadone at eight final concentrations ranging from 10 to 1500 µM diluted from a 100-mM stock solution in water. The test concentrations were chosen to enable adequate analysis of Michaelis--Menten kinetics. After one-min pre-incubation of this solution at 37 °C, the reactions were initiated by addition of human liver microsomes giving a final concentration of 0.5 mg/ml microsomal protein and incubations were performed in a shaking water bath at 37 °C for 40 min. Control incubations were performed in the absence of NADPH which was replaced with Tris--HCl. The reactions were terminated by addition of 40-µl ice-cold acetonitrile. Samples were kept on ice for at least 20 min and then centrifuged at 18,000*g* for 5 min at 4 °C to precipitate microsomal proteins. The supernatant was collected for the quantification of EDDP formation, which was analyzed by Ultra-Performance Liquid Chromatography PhotoDiode Array (UPLC-PDA, Waters) as described in the "Quantification of methadone and its metabolites by UPLC--PDA analysis" section.

The formation of the secondary metabolite EMDP from EDDP was investigated by incubating 1000-µM EDDP under the same conditions as described above for the microsomal methadone incubations. The kinetic parameters for the conversion of methadone by intestinal microsomes were determined under the same conditions as the incubations with liver microsomes after the incubation conditions were optimized with respect to microsomal protein levels (0.1--2 mg/ml protein) and incubation time (1--120 min) at 50-µM methadone.

The apparent maximum velocity (*V*~max~) and the apparent Michaelis--Menten constant (*K*~m~) describing the conversion of methadone to EDDP were determined using the Michaelis--Menten Eq. ([2](#Equ2){ref-type=""}):$$\documentclass[12pt]{minimal}
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                \begin{document}$$v = \frac{{V_{{\max}} \times \left[ S \right]}}{{K_{{\text{m}}} + \left[ S \right]}},$$\end{document}$$where \[*S*\] is the substrate concentration (µM) and *v* is the rate of EDDP formation (nmol/min/mg protein). *V*~max~ and *K*~m~ were obtained by fitting the data to Eq. ([2](#Equ2){ref-type=""}) in GraphPad Prism 5.0 (GraphPad Software Inc.). Data were collected from three independent experiments and each data point is presented as the mean value ± SD.

Determination of unbound fraction of methadone and EDDP in in vitro hiPSC-CM MEA assay medium and in human plasma {#Sec7}
-----------------------------------------------------------------------------------------------------------------

The rapid equilibrium dialysis (RED) assay was performed to determine the unbound fraction (*f*~u~) of methadone and EDDP in in vitro medium and in pooled human plasma using the protocol adapted from the manufacturer of the RED device (Thermo Fisher Scientific [@CR103]). In short, methadone or EDDP was added to the in vitro medium or pooled human plasma to reach a concentration of 150 µM in test sample solution and PBS was used as buffer. 300-µl test sample solution and 500-µl PBS were, respectively, added to the sample chamber and the buffer chamber of the RED insert, which was subsequently incubated for 5 h at 37 °C at 250 rpm on an orbital shaker to reach equilibrium (van Liempd et al. [@CR107]). Then, 25 µl of post-dialysis samples were collected from the sample chambers and transferred to test sample tubes followed by an addition of 25 µl PBS. Equal volumes of post-dialysis samples collected from the buffer chamber which were then mixed with 25 µl of in vitro medium or human plasma in the buffer sample tubes. Then, both samples were precipitated using 300-µl cold acetonitrile/water (90/10 v/v). The samples were put on ice for 30 min followed by centrifugation for 30 min at 15,000*g*. Then, supernatants were collected for UPLC--PDA analysis. The fraction unbound was calculated with Eq. ([3](#Equ3){ref-type=""}) (van Liempd et al. [@CR107]; Waters et al. [@CR110]):$$\documentclass[12pt]{minimal}
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The measurements were performed in triplicate in two independent experiments.

Quantification of methadone and its metabolites by UPLC--PDA analysis {#Sec8}
---------------------------------------------------------------------

The quantification of methadone and its metabolites was performed by UPLC--PDA analysis using a Waters Acquity UPLC H_class system (Etten-Leur, The Netherlands) equipped with a Waters Acquity BEH C18 (1.7 µm, 2.1 × 50 mm) column. For optimal separation, a gradient of 20-mM ammonium formate (pH = 5.7) (solvent A) and acetonitrile (solvent B) with a flow rate of 0.3 ml/min was applied as follows: the initial condition was 90:10 (A:B); then the gradient was increased linear to 98% B over 8 min; then set to the initial conditions in 2 min and re-equilibrated for 5 min. Retention times of methadone, EDDP and EMDP were 4.7, 4.4 and 6.3 min, respectively. Identification of methadone and its metabolites was based on comparison of their retention time and UV spectrum to those of commercially available reference compounds. Quantification was based on comparison of the respective peak areas to the peak areas of corresponding calibration curves which were prepared using the reference compounds (*R*^2^ \> 0.999).

Establishment of the PBK model for methadone and EDDP {#Sec9}
-----------------------------------------------------

In the present paper, a PBK model describing the ADME of methadone and its major metabolites in human was developed. Figure [3](#Fig3){ref-type="fig"} presents the schematic diagram of the PBK model including a submodel for the major metabolite EDDP and the compartments relevant for the ADME characteristics of methadone and EDDP. A submodel for EDDP was included to enable the prediction of internal concentrations of EDDP required to evaluate if EDDP will be formed in quantities that are relevant for cardiotoxicity. Considering that methadone is usually administered to the opioid dependent population or patients with chronic pain on a daily basis, a PBK model for repeated dosing of methadone was developed.Fig. 3Schematic diagram of the PBK model of methadone including a submodel for EDDP

The absorption rate constant (ka) and fraction absorbed (Fa) are two key parameters describing the absorption of methadone. The uptake of methadone from the gastrointestinal (GI) tract was reported to follow a first-order process (Yang et al. [@CR116]) with a mean ka value of 0.59/h obtained from several studies (Foster et al. [@CR42]; Wolff et al. [@CR114]). A mean Fa value of 0.88 was reported by Ke et al. ([@CR56]).

To describe the distribution, tissue: blood partition coefficients (*P*) of methadone and EDDP were obtained by dividing tissue: plasma partition coefficients by the corresponding blood/plasma ratio (BPr) obtained from subjects on methadone maintenance treatment (Hsu et al. [@CR50]), to correct for the differences in the distribution of the compounds in blood and plasma. The tissue: plasma partition coefficients of methadone and EDDP were calculated using prediction method 1 which applies the algorithms of Berezhkovskiy ([@CR16]) in the Simcyp Simulator V18 Release 1 (Certara, Sheffield, UK) requiring information on the fraction unbound in plasma (*f*~u,p~), lipophilicity (logP) and acid--base properties (pKa). The logP and pKa values of methadone were obtained from literature (Gerber et al. [@CR47]; Ke et al. [@CR56]). The logP and pKa of EDDP were obtained from Marvinsketch (ChemAxon, Hungary). The *f*~u,p~ of methadone was obtained from the in silico Simcyp prediction tool (Certara). The *f*~u,p~ value of 0.3 for EDDP was obtained from the study of Moody et al. ([@CR78]). The *f*~u,p~ of methadone and EDDP were also measured using pooled human plasma in the current study (see "RED assay" section). Since the influence of blood: tissue partition coefficients derived based on different *f*~u,p~ values on the model output was negligible (data not shown), the blood: tissue partition coefficients calculated with the Simcyp-derived *f*~u,p~ were used.

Liver was identified as the metabolizing organ in the PBK model since conversion of methadone was reported to primarily occur in the liver (Foster et al. [@CR43]; Totah et al. [@CR104]). Although Oda and Kharasch ([@CR83]) observed conversion of methadone in in vitro human intestinal microsomal incubations, the contribution of this intestinal metabolism to the elimination of methadone in vivo seems to be relatively small compared to the contribution of hepatic metabolism (Ke et al. [@CR56]). Given that only minor methadone depletion was observed in the incubations with pooled intestinal microsomes (see "[In vitro microsomal incubations](#Sec17){ref-type="sec"}"), intestinal metabolism was not considered in the model. Conversion of EDDP into EMDP was not included in the model since no EMDP measured in the microsomal incubations with EDDP (see "[In vitro microsomal incubations](#Sec17){ref-type="sec"}"). The in vitro *V*~max~ obtained from human liver microsomal incubations were scaled to the in vivo situation taking the total liver microsomal protein yield of 32 mg microsomal protein/g liver into account (Barter et al. [@CR13]).

After oral dosing, the urinary excretion of methadone and its metabolites accounts for up to 50% of the given dose (Ånggård et al. [@CR8]; Lugo et al. [@CR71]; Sullivan and Due [@CR99]) with the ratio of unchanged methadone to EDDP ranging between 1/1 and 1/5 (Kharasch et al. [@CR58], [@CR59]; Verebely et al. [@CR108]). Therefore, urinary excretion of methadone and EDDP was included in the PBK model. In addition, biliary excretion was included in the submodel of EDDP since the recovery of EDDP in feces was reported to account for up to 39% (Foster [@CR41]). The renal clearance of methadone (RCLmet) was set at 1.45 l/h which was the average of the values reported in different in vivo studies (Boulton et al. [@CR19]; Foster et al. [@CR42]; Kharasch et al. [@CR59]). The renal clearance (RCLeddp) and biliary excretion rate constant (kbile) of EDDP were obtained by the curve fitting option in Berkeley Madonna (version 8.3.18, UC Berkeley, CA, USA) in which the steady-state blood maximum concentration (*C*~max~) of EDDP obtained with the PBK model was fitted to the steady-state blood *C*~max~ of EDDP that was reported in subjects receiving methadone maintenance treatment with an oral dose of 57.5 mg/day (De Vos et al. [@CR29]). This resulted in the fitted rate constants for RCLeddp and Kbile of 19.99 l/h and 1.65/h (Table [1](#Tab1){ref-type="table"}), respectively. Kinetic model calculations and curve fitting were performed with Berkeley Madonna, applying Rosenbrock's algorithms for solving stiff systems. Model equations are shown in supplementary materials 2. Human physiological parameters used in the PBK model were obtained from Brown et al. ([@CR21]) (Table [1](#Tab1){ref-type="table"}). Table [2](#Tab2){ref-type="table"} shows the physicochemical parameters of methadone and EDDP.Table 1Physiological and biochemical parameters used in the PBK model for methadone and EDDPParametersSymbolValueReferencesBody weight (kg)BW70Brown et al. ([@CR21])Tissue volume (% body weight)Brown et al. ([@CR21]) LiverVLc0.0257 FatVFc0.2142 LungVLuc0.0076 Arterial bloodVAc0.0198 Venous bloodVVc0.0593 KidneyVKc0.004 HeartVHc0.0047 Slowly perfused tissueVSc0.5318 Rapidly perfused tissueVRc0.052 Cardiac output (l/h)Qc347.9Blood flow to tissue (% cardiac output)Brown et al. ([@CR21]) LiverQLc0.227 FatQFc0.052 KidneyQKc0.175 HeartQHc0.04 Slowly perfused tissueQSc0.188 Rapidly perfused tissueQRc0.318Absorption rate constant of methadone (/h)ka0.59Foster et al. ([@CR42]); Wolff et al. ([@CR114])Fraction absorbed of methadoneFa0.88Ke et al. ([@CR56])Renal clearance of methadone (l/h)RCLmet1.45Boulton et al. ([@CR19]); Foster et al. ([@CR42]); Kharasch et al. ([@CR59])Renal clearance of EDDP (l/h)RCLeddp19.99^a^Fitted valuesBiliary excretion rate constant of EDDP (/h)kbile1.65^a^Fitted values^a^Fitted value generated from EDDP data presented in the study of De Vos et al. ([@CR29])Table 2Physicochemical parameters for methadone and EDDPCompoundLogPpKaBPrTissue: blood partition coefficients^d^LiverFatSlowly perfused tissueRapidly perfused tissueLungKidneyHeartMethadone3.93^a^9.20^b^0.70^c^12.450.467.6712.451.777.564.9EDDP4.63^e^9.64^e^0.87^c^11.510.187.0611.511.566.954.48*BPr* blood/plasma ratio^a^Reported in Ke et al. ([@CR56])^b^Reported in Gerber et al. ([@CR47])^c^Reported in Hsu et al. ([@CR50])^d^Obtained by dividing tissue: plasma partition coefficients by the corresponding BPr values^e^Obtained from Marvinsketch (ChemAxon)

Evaluation of the PBK model {#Sec10}
---------------------------

To evaluate the performance of the PBK model developed, comparisons were made between predicted blood concentrations and area under the curve (AUC) values of methadone and in vivo blood concentrations and AUC values obtained in clinical studies with repeated daily oral administration at different doses of methadone. Given that the kinetics of methadone were reported based on plasma concentrations in clinical studies, the plasma concentration--time curves were extracted from graphs presented in the respective clinical studies using GetData Graph Digitizer 2.26[1](#Fn1){ref-type="fn"} and further converted to blood concentration--time curves by multiplying with the BPr value. For the evaluation of the PBK model, the model parameter body weight and the oral dose were chosen to match the values used in the clinical studies. The specifications of in vivo kinetic studies of methadone used to evaluate the PBK model are summarized in Table [4](#Tab4){ref-type="table"}.

Sensitivity analysis {#Sec11}
--------------------

A local parameter sensitivity analysis was performed to identify influential parameters on the predicted *C*~max~ in the heart venous blood during the steady-state phase. The normalized sensitivity coefficient (SC) was calculated with the following Eq. ([4](#Equ4){ref-type=""}):$$\documentclass[12pt]{minimal}
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Translation of in vitro concentration--response data to in vivo dose--response data using PBK modeling-based reverse dosimetry {#Sec12}
------------------------------------------------------------------------------------------------------------------------------

A change in the FPDc in the vitro field potential waveforms can be considered the surrogate endpoint for the QTc interval in the human ECG (Zwartsen et al. [@CR118]). Based on this consideration, PBK modeling-based reverse dosimetry was applied to translate in vitro concentration--response data on FPDc obtained from the hiPSC-CM using the MEA to in vivo dose--response curves for QTc. To this purpose, the in vitro unbound concentrations of methadone tested in the hiPSC-CM MEA assay were set equal to the unbound steady-state *C*~max~ of methadone in the heart venous blood by correcting the fraction unbound in plasma to a fraction unbound in blood using the BPr value in Eq. ([5](#Equ5){ref-type=""}):$$\documentclass[12pt]{minimal}
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                \begin{document}$${C}_{\mathrm{t}\mathrm{o}\mathrm{t}\mathrm{a}\mathrm{l}, \mathrm{h}\mathrm{u}\mathrm{m}\mathrm{a}\mathrm{n} \mathrm{b}\mathrm{l}\mathrm{o}\mathrm{o}\mathrm{d}}$$\end{document}$ values were extrapolated to in vivo oral doses by PBK modeling-based reverse dosimetry, using a bodyweight of 70 kg (Brown et al. [@CR21]). The same procedure was performed for each of the in vitro concentrations tested in the MEA. Thus, the entire in vitro concentration--response curve was translated to a predicted in vivo dose--response curve.

Evaluation of the PBK modeling-based reverse dosimetry approach {#Sec13}
---------------------------------------------------------------

To evaluate the performance of the PBK modeling-based reverse dosimetry approach, the predicted dose--response curves were compared to dose--response data for QTc prolongation obtained from published literature including single case reports, case series (Table S1), cross-sectional, retrospective and prospective studies (Table S2). To better illustrate the dose-dependent effect of methadone on QTc prolongation, individuals who have potential QTc prolonging risk factors including structural heart disease, electrolyte imbalance, hepatic impairment, concomitant use of medications that potentially prolong QTc or influence the metabolism of methadone (Stringer et al. [@CR98]) were excluded from case reports and case series used for the evaluation. Similar criteria could not be applied to the cross-sectional, retrospective and prospective studies due to the absence of detailed individual information on these risk factors. Potential QTc prolonging risk factors and exclusion criteria for these studies are summarized in Table S2. To facilitate the comparison between in vitro- and in vivo-derived values, both the absolute FPDc values obtained from the in vitro cardiotoxicity assay and the in vivo methadone-induced QTc prolongation on ECG were expressed as relative percentages by dividing the post-treatment FPDc and QTc values by the respective baseline values. For the studies in which baseline QTc data were not reported, a population baseline QTc was assumed as described in the study of Florian et al. ([@CR40]) in which baseline QTc was set equal to baseline QTc values identified in Wedam et al. ([@CR111]), with an average value of 407 ms (411 ms for female; 405 ms for male).

Benchmark dose modeling {#Sec14}
-----------------------

BMD analysis of predicted in vivo dose--response curves was performed to derive a BMD that can be used as point of comparison to evaluate the predicted dose--response data against therapeutic methadone levels reported in the literature. The benchmark response (BMR) was defined as a 10% change compared to the control. For the QTc, an effect of 10% change over the population baseline of 407 ms, amounting to a QTc of 450 ms is frequently used as a threshold for abnormal QTc prolongation (Anchersen et al. [@CR6]; Chou et al. [@CR25]; ICH [@CR102]; Mujtaba et al. [@CR79]; Treece et al. [@CR105]). The BMD values resulting in a BMR of 10% with lower and upper 95% confidence limit were defined as BMDL~10~ and BMDU~10~. The European Food Safety Authority (EFSA) web-tool[2](#Fn2){ref-type="fn"} integrated with the R-package PROAST version 66.40 developed by the Dutch National Institute for Public Health and the Environment (RIVM) was used for BMD analysis. In short, the continuous data from the predicted in vivo dose--response curves were fitted to a set of models including the Exponential, Hill, Inverse Exponential, and the Log-Normal Family models. According to the flow-chart described in the manual^2^ provided by EFSA, all fitted models excluding the FULL and NULL model were used for model averaging and a weighted average model was constructed to estimate model averaged confidence intervals using bootstrap sampling (Wheeler and Bailer [@CR112]). Weighting was based on the model's Akaike\'s Information Criterion (AIC) values where models with lower AIC values get a larger weight. 200 bootstrap data sets were run to calculate the final BMD confidence intervals from model averaging.

In vitro concentration--response cardiotoxicity data were analyzed using the same BMD approach to derive benchmark concentrations that induced a 20% change in the FPDc over the control (BMC~20~) for comparing the potency of methadone, EDDP and EMDP. The final BMC~20~ values were obtained by weighted averaging BMC~20~ values derived from all fitted models excluding the FULL and NULL model. For this analysis, a BMR of 20% was chosen being the lowest BMR allowing reliable curve fitting.

Results {#Sec15}
=======

In vitro cardiotoxicity in the hiPSC-CM MEA assay {#Sec16}
-------------------------------------------------

Figure [4](#Fig4){ref-type="fig"} shows the cardiotoxicity of methadone, EDDP and EMDP in hiPSC-CM as detected in the MEA. Methadone and its primary metabolite EDDP significantly prolonged the FPDc in a concentration-dependent manner with a BMC~20~ of 0.6 µM and 2.3 µM, respectively. Of interest to note is that the secondary metabolite EMDP induced an opposite effect, shortening the FPDc in a concentration-dependent manner with the concentration shortening the FPDc by 20% amounting to 3.8 µM. Both methadone and EDDP induced arrhythmia-like waveforms from 3 µM onwards; while, cessation of beating was observed upon the treatment of the hiPSC-CM with methadone and EDDP at 30 µM. EMDP caused beating arrest in certain wells at 30 µM without inducing arrhythmia-type waveforms within the test concentration range. The FPDc of hiPSC-CM treated with repeated application of 0.1% (v/v) DMSO in the vehicle control well was not significantly affected (Fig. S3).Fig. 4Concentration--response curves for the effect of methadone (circles), EDDP (squares) and EMDP (triangles) on FPDc in hiPSC-CM detected by the MEA. The response of the baseline condition (0.1% (v/v) DMSO) was set at 100%. Data represent the mean of 4--9 wells with in total 26--38 electrodes. Each data point represents the mean ± SD. Statistically significant changes in response compared to the solvent control are marked with \* with *p* \< 0.05: \*, *p* \< 0.01: \*\* and *p* \< 0.001: \*\*\*

In vitro microsomal incubations {#Sec17}
-------------------------------

Figure [5](#Fig5){ref-type="fig"} shows the concentration-dependent formation rate of EDDP from methadone by human liver microsomes, which followed Michaelis--Menten kinetics. The apparent *V*~max~ and *K*~m~ values obtained from the data, and the catalytic efficiency *(V*~max~/*K*~m~) are presented in Table [3](#Tab3){ref-type="table"}. No EMDP formation was measured in these incubations. In similar incubations using EDDP as the substrate, formation of EMDP was neither detectable. In incubations with intestinal microsomes applying the two highest methadone concentrations tested in liver microsomes (1000 and 1500 µM), formation of EDDP was less than 8% of the formation observed with liver microsomes at these concentrations. In addition, negligible formation of EDDP was observed in the incubation of 50-µM methadone with increasing incubation time up to 120 min and protein concentrations up to 2-mg/ml human intestinal microsomal protein. Also in these incubations, no EMDP formation was detected. This implied that conversion by intestinal microsomes was considered limited compared to conversion by human liver microsomes and therefore methadone conversion by intestinal tissue was not incorporated in the PBK model and, hence, no further kinetic constants were derived.Fig. 5Concentration-dependent formation of EDDP in incubations with human liver microsomes. Data represent the mean of three independent experiments. Each data point represents the mean ± SDTable 3Kinetic constants for formation of EDDP from methadone obtained from in vitro incubations with human liver and intestinal microsomesOrganSubstrateMetabolite*V*~max~ ± SD (nmol/min/mg microsomal protein)*K*~m~ ± SD (µM)Catalytic efficiency (µl/min/mg microsomal protein)^a^LiverMethadoneEDDP0.82 ± 0.026275 ± 26.782.97EMDPn.dn.d--EDDPEMDPn.dn.d--IntestineMethadoneEDDP0.058, 0.057 ^b^n.d--EMDPn.dn.d--*n.d.* not determined, since EDDP and EMDP were unable to be quantified (see text for details)^a^*V*~max~/*K*~m~ × 1000^b^Formation rate at 1000 µM and 1500 µM--Unable to calculate

Unbound fraction for methadone in in vitro hiPSC-CM MEA medium and in human plasma {#Sec18}
----------------------------------------------------------------------------------

Due to the use of serum-free medium in the hiPSC-CM MEA assay, the unbound fraction of methadone in the in vitro medium was relatively high, amounting to 0.79 ± 0.041 compared to the unbound fraction in pooled human plasma determined to be 0.055 ± 0.011. The unbound fraction of EDDP in the in vitro medium was 0.90 ± 0.072 and was 0.30 ± 0.015 in pooled human plasma.

Considering the large inter-individual variation in plasma protein binding for methadone observed in in vivo studies (Eap et al. [@CR32]; Olsen [@CR84]; Romach et al. [@CR91]; Wilkins et al. [@CR113]), also two extreme *f*~u,p~ values (0.034 and 0.22) obtained from the literature together with the Simcyp-derived and RED-derived *f*~u,p~ values (0.15 and 0.055, respectively) were used to translate in vitro effect concentrations to the total blood concentration as presented in Eq. ([5](#Equ5){ref-type=""}), which were subsequently subject to PBK modeling-based reverse dosimetry.

PBK model development and evaluation {#Sec19}
------------------------------------

To evaluate the performance of the human PBK model, the predicted methadone blood kinetics were compared to in vivo human data obtained from the literature. The specifications of in vivo studies on the subjects receiving methadone maintenance treatment that are used for the PBK model evaluation are summarized in Table [4](#Tab4){ref-type="table"}. As illustrated in Fig. [6](#Fig6){ref-type="fig"}, the developed PBK model accurately predicts the change of methadone blood concentrations during the last 24 h upon repeated oral methadone exposure as described in the study of Foster et al. ([@CR42]) and Liu et al. ([@CR66]). Table [4](#Tab4){ref-type="table"} further shows the detailed comparison between the model prediction and the in vivo kinetic data using steady-state blood *C*~max~ and AUC values on the last day of exposure as model outcomes. For methadone, the predicted kinetic values are in accordance with reported values expressing a 0.78- to 1.35-fold difference in *C*~max~ values and 0.76- to 0.97-fold difference in AUC values (Table [4](#Tab4){ref-type="table"}).Table 4Summary of in vivo kinetic studies and evaluation of the PBK model predictions for methadone steady-state blood *C*~max~ and AUC values based on the data derived from in vivo kinetic studiesMean body weight (kg)Mean methadone dose (mg/day)^a^In vivo *C*~max~ (ng/ml) ^b^In vivo AUC (ng · h/ml) ^b^Predicted *C*~max~ (ng/ml)Predicted AUC (ng · h/ml)Ratio predicted\
*C*~max~/in vivo C~max~Ratio predicted AUC/in vivo AUCReferences7470346.25097320.549670.930.97Foster et al. ([@CR42])^c^90100453.67889385.259690.850.76Liu et al. ([@CR66])^c^70^d^61216.0n.r293.145421.35--Diong et al. ([@CR30])64.757.5383.65978296.445910.780.77De Vos et al. ([@CR29])*n.r.* not reported, - unable to calculate^a^Free base form of methadone^b^Blood data were obtained by multiplying reported plasma data by the BPr value^c^In vivo *C*~max~ and AUC is the sum of data of enantiomers^d^The body weight of subjects was set equal to the value used in the PBK model since body weight of study subjects was not reportedFig. 6Blood concentration--time curves of methadone in human predicted with the PBK model (lines) and published in vivo data (dots) after a repeated oral dose of 70 mg/day for 60 days **a** (Foster et al. [@CR42]) and 100 mg/day for 30 days **b** (Liu et al. [@CR66])

Sensitivity analysis {#Sec20}
--------------------

Figure [7](#Fig7){ref-type="fig"} shows the most influential model parameters for the prediction of steady-state *C*~max~ in the heart venous blood upon exposure to oral repeated methadone doses of 20 and 200 mg. The results indicate that the normalized sensitivity coefficients of all PBK model parameters were not dose dependent until at least 200 mg/day and that the predicted steady-state *C*~max~ in the heart venous blood is most sensitive to the oral fraction absorbed and the body weight with normalized SC values above 0.8. The parameters related to liver metabolism (volume of liver, liver microsomal protein yield, unscaled maximum rate of methadone metabolism) also substantially influence the model outcome with normalized SC values of 0.6. The absorption rate constant and the partition coefficient rapidly perfused tissue to blood of methadone are less influential with normalized SC value of 0.25 and 0.1, respectively.Fig. 7Normalized SCs of PBK model parameters for the prediction of steady-state *C*~max~ of methadone in the heart venous blood upon oral repeated doses of 20 mg/day (white bars) and 200 mg/day (black bars). Model parameters with normalized SC with an absolute value higher than 0.1 (dotted lines) are shown. *BW* body weight, *VLc* fraction of liver, *PRmet* partition coefficient rapidly perfused tissue:blood of methadone, *ka* absorption rate constant, *Fa* oral fraction absorbed, *MPL* liver microsomal protein yield, *Vmaxc* unscaled maximum rate of methadone metabolism in liver, *Km* Michaelis--Menten constant for methadone metabolism in liver

Translation of in vitro concentration--response data into in vivo dose--response data using PBK modeling-based reverse dosimetry {#Sec21}
--------------------------------------------------------------------------------------------------------------------------------

Although EDDP induced concentration-dependent prolongation of FPDc in the in vitro assay, the free blood *C*~max~ of EDDP, after an oral dose of 57.5 mg/day, was estimated to be 0.05 µM based on EDDP data reported in De Vos et al. ([@CR29]). Using the current PBK model, the free blood *C*~max~ of EDDP was predicted to be 0.17 µM at a relatively high dose level of methadone of 200 mg/day. Both the reported and predicted free blood *C*~max~ of EDDP are substantially lower than unbound concentrations causing cardiotoxicity in the hiPSC-CM MEA assay (unbound BMC~20~ = 2.07 µM) (Fig. [4](#Fig4){ref-type="fig"}). To reach the unbound BMC~20~ value of 2.07 µM, a methadone dose level of 2600 mg/day was estimated to be required, which is 22-fold higher than the highest clinical relevant dose of 120 mg/day (Chou et al. [@CR25]). Therefore, the cardiotoxicity of EDDP was not considered to play a role in methadone-induced cardiotoxicity and, thus, also not considered for the reverse dosimetry.

Upon correction for protein binding performed using the values for *f*~u,m~ and *f*~u,p~ described above, the in vitro concentration--response curve of methadone obtained in the hiPSC-CM as detected by the MEA was translated to in vivo dose--response curves for human cardiotoxicity using the developed PBK model. As mentioned in the "unbound fraction for methadone" section, *f*~u.m~ of 0.79 was used to correct for protein binding of methadone in the in vitro medium; while for the in vivo situation, four different *f*~u,p~ values were used including the experimental *f*~u,p~ value obtained from pooled human plasma, an in silico-derived *f*~u,p~ value and two extreme *f*~u,p~ values obtained from the literature (Eap et al. [@CR32]; Foster et al. [@CR42]; Moody et al. [@CR78]; Olsen [@CR84]; Romach et al. [@CR91]; Wilkins et al. [@CR113]). This resulted in four predicted in vivo dose--response curves for methadone-induced cardiotoxicity, one for each of the *f*~u,p~ values (Fig. [8](#Fig8){ref-type="fig"}). These predicted dose--response curves were subsequently compared to available in vivo human data.Fig. 8Predicted dose--response curves for cardiotoxicity of methadone obtained using PBK modeling-based reverse dosimetry compared to in vivo dose--response data derived from literature. The curves represent the prediction based on a *f*~u,p~ of 0.22 (black line), 0.15 (red line), 0.055 (blue line) and 0.034 (green line). Symbols represent the data obtained from case reports, case series of individuals (orange triangles) (Esses et al. [@CR35]; Fredheim et al. [@CR44]; Krantz et al. [@CR61]) and other studies as follows: Bart et al. ([@CR14]) (purple circle); Carlquist et al. ([@CR22]) (orange square); Chang et al. ([@CR23]) (green circle) Chowdhury et al. ([@CR26]); (dark blue cross); Cruciani et al. ([@CR28]) (green cross) Eap et al. ([@CR31]); (green star); Ehret et al. ([@CR34]) (dark blue triangle) Fareed et al. ([@CR39]); (dark blue circle) Heesch et al. ([@CR49]); (dark blue star) Krantz et al. ([@CR62]); (orange circles) Maremmani et al. ([@CR73]); (green square); Martell et al. ([@CR74]) (green triangle) Peles et al. ([@CR86]); (orange star); Reddy et al. ([@CR87]) (orange circles) Roy et al. ([@CR92]); (dark blue square). The in vivo data are summarized in Table S1 and S2 (color figure online)

Evaluation of the PBK modeling-based reverse dosimetry approach and BMD analysis of predicted dose--response data {#Sec22}
-----------------------------------------------------------------------------------------------------------------

To evaluate the performance of the PBK modeling-based reverse dosimetry approach, the dose--response data for QTc prolongation obtained from case reports, case series, cross-sectional, retrospective and prospective studies were compared with the predicted dose--response curves for QTc prolongation taking different *f*~u,p~ values into account. This comparison, presented in Fig. [8](#Fig8){ref-type="fig"}, reveals that the predicted in vivo dose--response curves for QTc prolongation were comparable with reported in vivo data. The prediction of QTc prolongation with the *f*~u,p~ value of 0.15 obtained from Simcyp is best in line with the majority of reported QTc prolongation data of individual cases. The QTc prolongation data reported in population studies, however, were more close to the predicted dose--response curve with the *f*~u,p~ value of 0.055 obtained from the RED assay.

To further evaluate the model predictions a BMD analysis was performed. BMDL~10~ values were derived and used as points of comparison. Figure [9](#Fig9){ref-type="fig"} presents the BMDL~10~ derived from the dose--response curves presented in Fig. [8](#Fig8){ref-type="fig"}, predicted with the different *f*~u,p~ values while also presenting therapeutic dose levels of methadone. The comparison presented in Fig. [9](#Fig9){ref-type="fig"} reveals that the predicted BMDL~10~ values overlap with the therapeutic methadone dose levels. The predicted BMDL~10~ values for methadone-induced cardiotoxicity based on high *f*~u,p~ values of 0.22 and 0.15 are 1.7- and 2.4-fold higher, respectively, than the recommended initial dose for opioid-native patients (10 mg/day), and the predicted BMDL~10~ values based on low *f*~u,p~ values of 0.055 and 0.034 are 2.2- and 3.6-fold higher, respectively, than the recommended initial dose for opioid users (30 mg/day) (Chou et al. [@CR25]; BCCSU [@CR20]). This indicated that these therapeutic dose levels are below the dose levels predicted to result in 10% change, an effect size that can be used as a threshold to evaluate abnormal QTc prolongation (Anchersen et al. [@CR6]; Chou et al. [@CR25]; ICH [@CR102]; Mujtaba et al. [@CR79]; Treece et al. [@CR105]). The maintenance dose of 60--120 mg methadone/day (Chou et al. [@CR25]; BCCSU [@CR20]) is, however, 0.6- to 7.2-fold higher than the predicted BMDL~10~ values in all scenarios, pointing at a potential cardiotoxic effect in especially individuals with relatively lower plasma protein binding (higher *f*~u,p~). Detailed information on the BMD analysis can be found in the supplementary materials 1 Tables S3--S7 and the BMD values are summarized in Table S7.Fig. 9Comparison of BMDL values derived from the predicted dose--response curves for human cardiotoxicity of methadone presented in Fig. [8](#Fig8){ref-type="fig"} (lines) and therapeutic dose levels reported in the literature (boxes filled with horizontal lines)

Discussion {#Sec23}
==========

The aim of the present study was to investigate whether human in vivo cardiotoxicity could be predicted by a novel testing strategy combining the in vitro toxicity assay with hiPSC-CM in a MEA and PBK modeling-based reverse dosimetry. Methadone was used as the model compound given that for this drug, both kinetic and clinical human data for evaluation of predictions made were available.

The in vitro electrophysical cardiotoxicity was detected using hiPSC-CM combined with the MEA technology, which can capture the overall effects on multiple ion channels on the extracellular field potential. The change in FPDc in the in vitro obtained field potential waveforms can be considered a surrogate endpoint for the QTc interval in the human ECG (Zwartsen et al. [@CR118]), the parameter known to be indicative for methadone-induced cardiotoxicity (Mujtaba et al. [@CR79]). The results show that methadone induced a concentration-dependent prolongation of FPDc which is in line with the study of Kuryshev et al. ([@CR64]) reporting that methadone prolonged the action potential duration using patch clamp recordings in human cardiomyocytes. Studies using mammalian cells transfected with cardiac ion channels revealed that the prolonged effect on FPDc can be ascribed to the inhibition of the hERG and sodium channels (Eap et al. [@CR31]; Kuryshev et al. [@CR64]). The major methadone metabolite EDDP appeared to also prolong the FPDc albeit with lower potency than methadone. This lower potency of EDDP is in line with the fact that EDDP was reported to be a weaker hERG channel blocker compared to methadone (Eap et al. [@CR31]; Katchman et al. [@CR55]); while, effects on other ion channels such as sodium channel may contribute to the observed EDDP-induced FPDc prolongation effect (Mishra et al. [@CR77]). Neither FPDc prolongation nor arrhythmia-type waveforms were observed upon exposure of the hiPSC-CM to EMDP which is in accordance with the previous study reporting EMDP to not inhibit hERG channels (Eap et al. [@CR31]). Given that the in vivo total plasma concentration of EMDP has been reported to be less than 0.04 µM after clinical relevant dosing (Alburges et al. [@CR4]), it can be concluded that the in vitro effects of EMDP in the hiPSC-CM MEA assay, with an in vitro BMC~20~ for decreasing FPDc of 3.8 µM, would not be relevant in in vivo. Thus, the methadone-induced prolongation of the FPDs is unlikely to be counteracted by EMDP and the cardiotoxicity of EMDP was not further taken into account.

The evaluation of the developed PBK model against literature data available on steady-state blood *C*~max~ and AUC values of methadone (De Vos et al. [@CR29]; Diong et al. [@CR30]; Foster et al. [@CR42]; Liu et al. [@CR66]), indicated that the model was able to adequately predict the kinetics of methadone with differences being less than twofold, which is generally accepted as an adequate predictive performance (Badhan et al. [@CR11]; WHO [@CR115]).

It is generally assumed that the unbound concentration is responsible for the clinical response of a drug (Smith et al. [@CR94]). Given that methadone is a lipophilic drug with basic properties, the extent of protein binding may play an important role in determining the free concentration and influence the therapeutic or toxic effects of methadone. Given that in vivo experimental data report variation in the *f*~u,p~ values of methadone, the PBK modeling-based reverse dosimetry was performed taking into account different values for *f*~u,p~. It is reported that the fraction of unbound methadone is significantly correlated to the plasma concentration of alpha1-acid glycoprotein (AAG) (Abramson [@CR2]; Yang et al. [@CR116]), which is known to be influenced by physiological and pathologic conditions of the subject (Eap et al. [@CR32]). The 1.5- to 6.5-fold difference in the four f~u,p~ values used for the PBK modeling-based reverse dosimetry are in line with the 2- to 20-fold variation of the AAG concentration among individuals (Taguchi et al. [@CR100]).

The predicted dose--response curves obtained from the PBK modeling-based reverse dosimetry, using the respective *f*~u,p~ values were in line with in vivo data available from case reports, case series, cross-sectional, retrospective and prospective studies on methadone induced effects on in vivo QTc prolongation available in the literature (Fig. [8](#Fig8){ref-type="fig"}). This further validates the developed PBK model and provides support for the novel in vitro--in silico testing strategy for prediction of cardiotoxicity in human.

It is of interest to note that the predictions with high *f*~u,p~ values (0.22 and 0.15) are more in line with data obtained from individual case series; while, the data obtained with lower *f*~u,p~ values (0.055 and 0.034) especially match the data from population studies. The reasons underlying this observation remain to be elucidated but may be related to the fact that the concentration of AAG increases under the conditions of heroin addiction (Garrido et al. [@CR46]), HIV infection (Barrail-Tran et al. [@CR12]), and cancer (Huang and Ung [@CR51]). Given that the subjects in the epidemiological studies were associated with those physiological and pathologic conditions, smaller *f*~u,p~ values would be expected; while, the individual case series were selected using criteria that specifically exclude these potential factors that interfere with the concentration of AAG.

To further evaluate the in vitro--in silico predictions for human cardiotoxicity of methadone, BMDL~10~ values derived from predicted dose--response curves were compared to therapeutic doses. The BMDL~10~ values appeared to overlap with the therapeutic dose levels. Given the fact that a BMDL~10~ value is generally considered a dose level that is comparable to a no observed adverse effect level (EFSA [@CR36]), and 10% effect is an effect size used as a threshold to evaluate abnormal QTc prolongation (Anchersen et al. [@CR6]; Chou et al. [@CR25]; ICH [@CR102]; Mujtaba et al. [@CR79]; Treece et al. [@CR105]), doses lower than the predicted BMDL~10~ values would be expected to be without an effect on QTc prolongation, which is in line with the observation that the predicted BMDL~10~ values based on high *f*~u,p~ values and low *f*~u,p~ values are two- to threefold higher than the recommended initial dose for opioid-native patients (10 mg/day) and opioid users (30 mg/day), respectively (Chou et al. [@CR25]; BCCSU [@CR20]). The fact that the BMDL~10~ values obtained with the relatively higher *f*~u,p~ values are 2.5- to sevenfold lower than the maintenance dose (60 mg/day), may explain the QTc prolongation observed in some methadone maintenance treatment patients given these therapeutic maintenance dose levels. This confirms the need for particular cautions (intensive ECG monitoring and determining arrhythmia risk factor) for patients receiving high doses of methadone (\> 100 mg) (Florian et al. [@CR40]; Mujtaba et al. [@CR79]; Treece et al. [@CR105]). Krantz et al. ([@CR61]) reported that methadone induced Tdp in patients, without the presence of other risk factors, prescribed an average dose of 400 mg/day, which is consistent with our predictions given the fact that this dose is even fourfold higher than the BMDL~10~ value (109 mg/day) derived from the predictions based on the lowest *f*~u,p~ values. The results of our study indicate that especially subjects with lower levels of plasma protein binding (higher *f*~u,p~) of methadone may be a group at extra risk.

The results of the present study indicate that *f*~u,p~ may be a key parameter causing interindividual differences in the cardiotoxicity of methadone. The exact magnitude of the effect of changes in protein binding on toxicity, however, is not always straightforward since this is an interplay between the available fraction at the site of action, metabolism and excretion and may, i.e., require detailed information on the fate of a compound within cells/the human body which is often not available. Moreover, the variability in other factors that influence the concentration in the heart venous blood may also cause variation in cardiotoxic effects in individuals. Based on the sensitivity analysis, the *C*~max~ in heart venous blood is also influenced by metabolism-related parameters. A major enzyme involved in the metabolism of methadone to EDDP is CYP2B6, a cytochrome P450 that shows large interindividual variability due to genetic polymorphism (Kharasch [@CR57]). It would be of interest to integrate also this variability in the PBK model-based reverse dosimetry approach and predict its influence on the in vivo effects of methadone. This is a topic beyond the aim of the present study, that is currently under investigation. In addition, given that methadone is the racemic mixture of *R*- and *S*-methadone and the latter enantiomer is mainly responsible for the cardiotoxic effects (Ansermot et al. [@CR9]; Eap et al. [@CR31]; Lin et al. [@CR65]), it would also be of interest to predict methadone induced cardiotoxicity distinguishing between the *R*- and *S*-enantiomers.

In the present study, we demonstrated the integration of the hiPSC-CM MEA data and PBK modeling-based reverse dosimetry to assess the in vivo cardiotoxicity of methadone in human. This in vitro--in silico approach enabled the translation of the in vitro concentration--response data on cardiotoxicity to predicted in vivo dose--response data for methadone-induced QTc prolongation in human. Comparison of model predictions to in vivo data revealed that the novel testing strategy provided adequate predictions for both in vivo kinetics and cardiotoxicity of methadone, also pinpointing to an important role for binding to plasma proteins in determining potential interindividual differences in sensitivity towards the cardiotoxic effects of methadone. The present study provides a proof-of-principle of using PBK modeling-based reverse dosimetry for QIVIVE to predict cardiotoxicity in human, providing a novel testing strategy for cardiac safety.
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ADME

:   Absorption, distribution, metabolism and excretion

AIC

:   Akaike's Information Criterion

AUC

:   Area under the curve

BMD

:   Benchmark dose

BMDL~10~---BMDU~10~

:   Lower and upper 95% confidence limit of BMD resulting in 10% effect

BMR

:   Benchmark response

BMC~20~

:   Benchmark concentration that induced a 20% change

EDDP

:   2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine

EMDP

:   2-Ethyl-5-methyl-3,3-diphenylpyrroline

FPD

:   Field potential duration

FPDc

:   Field potential duration corrected for beat rate

hERG

:   Human ether-à-go-go-related gene

hiPSC-CM

:   Human induced pluripotent stem cell-derived cardiomyocytes

C~max~

:   Maximum concentration

MEA

:   Multi electrode array

QIVIVE

:   Quantitative in vitro to in vivo extrapolation

Tdp

:   Torsade de pointes

*f*~u,p~

:   Unbound fraction in human plasma

*f*~u,m~

:   Unbound fraction in in vitro medium
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